新诊断胶质母细胞瘤的 upfront 磁共振引导立体定向激光消融:与匹配的仅活检患者队列生存结局比较的多中心回顾
该多中心回顾性研究纳入24例接受 upfront 激光消融(LA)的新诊断胶质母细胞瘤(nGBM)患者,并与24例匹配的仅活检患者比较。LA组中位总生存(OS)14.4个月、无进展生存(PFS)4.3个月,仅活检组分别为15.8个月和5.9个月。基于热损伤阈值(TDT)线的预后分组与疾病特异性死亡(P=.03)和进展(P=.05)风险降低相关;年龄<70岁(P=.02)和肿瘤体积<11 cc(P=.03)是OS的有利预后因素。
要点
- LA组中位OS为14.4个月,仅活检组为15.8个月;中位PFS分别为4.3个月和5.9个月。
- 基于TDT线的有利预后分组与较低的疾病特异性死亡风险(P=.03)和进展风险(P=.05)相关。
- 年龄<70岁(P=.02)和肿瘤体积<11 cc(P=.03)是OS的有利预后因素。
核心结论
- 最大程度肿瘤覆盖的LA后联合放化疗是nGBM患者的有效治疗方式,优于仅活检队列。
- TDT线预后分组是LA后疾病特异性死亡和进展的独立预测因素。
研究设计与样本
- 多中心回顾性研究,纳入24例在克利夫兰诊所、圣路易斯华盛顿大学和耶鲁大学(2011年6月至2014年12月)接受 upfront LA 后行放化疗的nGBM患者。
- 从171例接受活检后放化疗的nGBM患者中,按年龄(<70岁 vs ≥70岁)、性别、肿瘤位置(深部 vs 脑叶)和体积(<11 cc vs ≥11 cc)匹配24例仅活检患者。
- 结局指标为无进展生存(PFS)、总生存(OS)以及疾病特异性PFS和OS。
- 根据热损伤阈值(TDT)线定义的肿瘤消融范围,识别出三个预后分组。
主要发现
- LA组(n=24)中位肿瘤体积为9.3 cm3,仅活检组(n=24)为8.2 cm3。
- LA组中位OS估计值为14.4个月,仅活检组为15.8个月;LA组中位PFS为4.3个月,仅活检组为5.9个月。
- 多因素分析中,有利TDT线预后分组与其他组(包括仅活检队列)相比,与较低的疾病特异性死亡发生率(P=.03)和进展发生率(P=.05)相关。
- 年龄<70岁(P=.02)和肿瘤体积<11 cc(P=.03)是OS的有利预后因素。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Laser ablation (LA) is used as an upfront treatment in patients with deep seated newly diagnosed Glioblastoma (nGBM). OBJECTIVE: To evaluate the outcomes of LA in patients with nGBM and compare them with a matched biopsy-only cohort. METHODS: Twenty-four nGBM patients underwent upfront LA at Cleveland clinic, Washington University in St. Louis, and Yale University (6/2011-12/2014) followed by chemo/radiotherapy. Also, 24 out of 171 nGBM patients with biopsy followed by chemo/radiotherapy were matched based on age (< 70 vs ≥ 70), gender, tumor location (deep vs lobar), and volume (<11 cc vs ≥11 cc). Progression-free survival (PFS), overall survival (OS), and disease-specific PFS and OS were outcome measures. Three prognostic groups were identified based on extent of tumor ablation by thermal-damage-threshold (TDT)-lines. RESULTS: The median tumor volume in LA (n = 24) and biopsy only (n = 24) groups was 9.3 cm3 and 8.2 cm3 respectively. Overall, median estimate of OS and PFS in LA cohort was 14.4 and 4.3 mo compared to 15.8 mo and 5.9 mo for biopsy only cohort. On multivariate analysis, favorable TDT-line prognostic groups were associated with lower incidence of disease specific death (P = .03) and progression (P = .05) compared to other groups including biopsy only cohort. Only age (<70 yr, P = .02) and tumor volume (<11 cc, P = .03) were favorable prognostic factors for OS. CONCLUSION: The maximum tumor coverage by LA followed by radiation/chemotherapy is an effective treatment modality in patients with nGBM, compared to biopsy only cohort. The TDT-line prognostic groups were independent predictor of disease specific death and progression after LA.
引用
- Mohammadi AM, Sharma M, Beaumont TL, et al. Upfront Magnetic Resonance Imaging-Guided Stereotactic Laser-Ablation in Newly Diagnosed Glioblastoma: A Multicenter Review of Survival Outcomes Compared to a Matched Cohort of Biopsy-Only Patients. Neurosurgery. 2019. PMID: 30476325. doi:10.1093/neuros/nyy449
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。